Caris Life Sciences (CAI) Stock Overview
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CAI from our risk checks.
CAI Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Caris Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.59 |
| 52 Week High | US$42.50 |
| 52 Week Low | US$17.15 |
| Beta | 0 |
| 1 Month Change | -15.50% |
| 3 Month Change | -31.53% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -33.61% |
Recent News & Updates
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon
Feb 05
Recent updates
Whole Genome Push Will Strain Margins Yet Could Eventually Support A Stronger Future
Catalysts About Caris Life Sciences Caris Life Sciences provides comprehensive molecular profiling and data-driven precision medicine solutions across tissue and blood for oncology and related applications. What are the underlying business or industry changes driving this perspective?Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon
Feb 05Caris Life Sciences: Stronger Fundamentals, Same Conclusion
Dec 24Shareholder Returns
| CAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.0% | -3.9% | -2.2% |
| 1Y | n/a | 22.8% | 16.9% |
Return vs Industry: Insufficient data to determine how CAI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CAI performed against the US Market.
Price Volatility
| CAI volatility | |
|---|---|
| CAI Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CAI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CAI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 1,846 | David Halbert | www.carislifesciences.com |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers.
Caris Life Sciences, Inc. Fundamentals Summary
| CAI fundamental statistics | |
|---|---|
| Market cap | US$5.25b |
| Earnings (TTM) | -US$537.96m |
| Revenue (TTM) | US$812.03m |
Is CAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAI income statement (TTM) | |
|---|---|
| Revenue | US$812.03m |
| Cost of Revenue | US$271.00m |
| Gross Profit | US$541.04m |
| Other Expenses | US$1.08b |
| Earnings | -US$537.96m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.90 |
| Gross Margin | 66.63% |
| Net Profit Margin | -66.25% |
| Debt/Equity Ratio | 65.6% |
How did CAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/09 06:57 |
| End of Day Share Price | 2026/03/06 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Caris Life Sciences, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Michael Ryskin | BofA Global Research |
| Mark Massaro | BTIG |